Human Recombinant IGF-BP7 (from E. coli)

Supplier: Peprotech

350-09-5UG 350-09-25UG 350-09-100UG 350-09-250UG 350-09-500UG 350-09-1MG
10774-464EA 139.89 USD
10774-464 10774-466 10774-468 10774-470 10774-472 10774-474
Human Recombinant IGF-BP7 (from E. coli)
Proteins and Peptides

IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently, there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP7 is expressed in a wide range of normal human tissues, and it generally shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin. It plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF-induced differentiation of skeletal myoblasts, without affecting IGF-induced proliferation. Additionally, IGF-BP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF-independent mechanism, which causes a delay in the G1 phase of the cell cycle and increased apoptosis. Recombinant Human IGF-BP7 is a 26.4 kDa protein consisting of 256 amino acid residues.


Información para pedidos: For research use only. Not for use in diagnostic or therapeutic procedures.

Order Now


Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR